

Human TNFRSF19 Protein

Cat. No. TNF-HM019

Description

Source	Recombinant Human TNFRSF19 Protein is expressed from HEK293 with His tag at the C-terminus. It contains Glu30-Leu170.
Accession	Q9NS68-1
Molecular Weight	The protein has a predicted MW of 16.55 kDa. Due to glycosylation, the protein migrates to 25-40 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC

Formulation and Storage


Formulation	Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 $\mu\text{g}/\text{ml}$ is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3-6 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

A novel susceptibility gene TNFRSF19, which encodes an orphan member of the TNF receptor superfamily known to be associated with nasopharyngeal carcinoma (NPC) and lung cancer risk. TNFRSF19, a susceptibility gene for nasopharyngeal carcinoma and other cancers, functions as a potent inhibitor of the TGF β signaling pathway.

Assay Data


Bis-Tris PAGE



Human TNFRSF19 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Assay Data



The purity of Human TNFRSF19 is greater than 95% as determined by SEC-HPLC.